HUNTX PHARMA | Linksium
Back to portfolio

HUNTX PHARMA

Maturation

Self-treat neurological diseases related to axonal transport defects

profilePhoto   Elodie Lages
Linksium Contact Elodie Lages +33 (0)7 76 23 29 19 elodie.lages@linksium.fr
Depositphotos 208672538 stock photo conceptual illustration of neuron cells

Benefits

  • Cure
  • Restore the functions of mutated genes
  • Restore axonal transport

Key words

  • Drugs
  • Neurological diseases
  • Innovation

Intellectual Property

  • 1 patent

Partnerships & Rewards

  • 2022 i-Lab French Deeptech Innovation Competition Winner - Grand Prix

Laboratory

  • GIN

Institution

  • UGA

Linksium Continuum

  • Maturation
  • Incubation

Context

Axonal transport allows neuronal cells to exchange information and nutrients that are essential for their functioning and survival. Over the past 20 years, more than 50 illnesses including Huntington's disease (HD) have been shown to be caused by mutations in axonal transport genes.

Technology

We have identified a key enzymatic reaction that controls axonal transport from the cortex to the BDNF striatum, an important nutrient for the survival of neurons in the striatum. With our drug HX127 we inhibit this enzyme which allows to restore this transport.

Advantages

By restoring the deficient BDNF transport in Huntington's disease we can restore not only the physiological defect but also the impaired motor, cognitive and psychiatric functions HD. We demonstrated this in a mouse model of HD.

State of progress

We demonstrated the benefit of HX127 in HD mice and in neurons of HD patients. Our next step is to finalize the R&D to determine the best dose of treatment and the treatment regimen. Then we can validate the safety in regulatory preclinical studies before demonstrating the benefit in patients.

Applications

HX127 will finally treat HD patients! They will not only be able to live but to live normally! Thanks to our platform technology we will be able to address other diseases such as Rett syndrome or Alzheimer's disease.

Featured articles

Nora Dempsey and deeptech innovations

1, 2 and 3 startups for Nora Dempsey, National Medal of Innovation 2021

Nora Dempsey is one of the four winners of National Medal for Innovation 2021 awarded by CNRS. Nora Dempsey, born in Ireland, has gained an international recognition for her research in Grenoble on...

Read the article
Dd amiral 2018 Frenchweb

Amiral Technologies, la startup IA grenobloise spécialisée dans les solutions de maintenance prédictive, intègre Station F

An ambitious promise: to invent a zero-defect and zero-downtime future for industry. Amiral Technologies, a startup co-founded and boosted by Linksium, based on the technological prowess of the Gre...

Read the article
Close projects index

U

X